Complement-inhibiting effect of ovarian cancer antigen CA-125

Cancer Lett. 2006 May 8;236(1):54-7. doi: 10.1016/j.canlet.2005.05.002. Epub 2005 Jun 27.

Abstract

Malignant transformation of ovarian cells of surface epithelial origin is associated with expression of a membrane-spanning glycoprotein, cancer antigen (CA)-125. The bulk of the putative CA-125 molecule is comprised a very large, folded, multivalent, mucin-like exodomain. That the extracellular motif of CA-125 exerts immunosuppressive effects which promote tumor progression has been suggested. We report that CA-125 attenuates complement lysis of antibody-sensitized cells. The secreted form of CA-125 derived from culture medium of the human ovarian adenocarcinoma cell line OVCAR-3 caused a dose-response inhibition of sheep erythrocyte hemolysis. Moreover, OVCAR-3 cells became prone to complement attack (trypan blue uptake) mediated by a gonadotropin-releasing hormone receptor antibody when (membrane-bound) CA-125 was excised/removed by trypsin/washing; this effect was counteracted by replacement with (soluble) CA-125. It is conceivable that CA-125 entraps/sheds effectors of the complement cascade.

MeSH terms

  • Animals
  • Antibodies / immunology
  • Antibodies / pharmacology
  • CA-125 Antigen / isolation & purification
  • CA-125 Antigen / pharmacology*
  • Cell Line, Tumor / immunology*
  • Complement Activation / drug effects*
  • Complement Hemolytic Activity Assay
  • Complement Inactivating Agents / pharmacology*
  • Cytotoxicity, Immunologic / drug effects
  • Dose-Response Relationship, Drug
  • Erythrocytes / drug effects
  • Erythrocytes / immunology
  • Female
  • Hemolysis
  • Humans
  • Ovarian Neoplasms
  • Receptors, LHRH / immunology
  • Sheep
  • Time Factors

Substances

  • Antibodies
  • CA-125 Antigen
  • Complement Inactivating Agents
  • Receptors, LHRH